Cessatech A/S Share Price

Stocks

End-of-day quote NORDIC GROWTH MARKET Other stock markets 15/07/2026			5-day change	1st Jan Change
17.75 ^DKK	-1.11%		-5.08%	+11.22%

12/06	Cessatech partners with Rigshospitalet for CT004 development	FW
12/06	Cessatech A/S and University Hospital of Copenhagen, Rigshospitalet Enter Collaboration to Advance Intravenous Formulation of Melatonin for Post-Anaesthesia Delirium in Children	CI

Market Cap	30Cr 4.54Cr 3.97Cr 3.67Cr 3.37Cr 6.37Cr 437.21Cr 6.48Cr 44Cr 17Cr 213.5Cr 17Cr 17Cr 737.1Cr	P/E 2023	-3.77x	P/E 2024	-13.9x
Enterprise Value	28Cr 4.35Cr 3.8Cr 3.51Cr 3.23Cr 6.1Cr 418.96Cr 6.21Cr 42Cr 16Cr 204.59Cr 16Cr 16Cr 706.34Cr	EV / Sales 2023	-	EV / Sales 2024	7,77,32,546x
Free-Float	-	Yield 2023 *	-	Yield 2024	-

12/06	Cessatech partners with Rigshospitalet for CT004 development	FW
12/06	Cessatech A/S and University Hospital of Copenhagen, Rigshospitalet Enter Collaboration to Advance Intravenous Formulation of Melatonin for Post-Anaesthesia Delirium in Children	CI
28/05	Cessatech narrows losses	FW
28/05	Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
27/02	Cessatech A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
27/02	Cessatech's Operating Loss Decreased in 2025	FW
27/02	Cessatech A/S Auditor Raises 'Going Concern' Doubt	CI
13/11	Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/11	Cessatech increases operating loss	FW
31/25/31	Cessatech Nears Launch of Pediatric Pain Medication in US Market	FW
21/25/21	Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
21/25/21	Cessatech Narrows Losses in Second Quarter	FW
15/25/15	Cessatech Submits Application to EMA for CT001 Pediatric Pain Relief	FW

12/06	Cessatech enters collaboration with University Hospital of Copenhagen, Rigshospitalet, to advance an intravenous formulation of melatonin for post-anaesthesia delirium (CT004) in children	AQ
28/05	First Quarter Report Q1-2026	AQ
30/03	Minutes from the Annual General Meeting in Cessatech A/S	AQ
13/03	Cessatech convenes its Annual General Meeting	AQ
27/02	Cessatech A/S Announces Financial Results for the Full Year 2025	AQ

Manager	Title	Age	Since
Jes Trygved CEO	Chief Executive Officer	53	01/01/2020
Sarah Margaux Toft-Jørgensen DFI	Director of Finance/CFO	-	01/11/2025
Martin Juhl CTO	Chief Tech/Sci/R&D Officer	-	01/03/2022

Director	Title	Age	Since
Martin Olin CHM	Chairman	57	01/01/2022
Flemming Steen Jensen BRD	Director/Board Member	65	01/01/2020
Charlotte Videbaek BRD	Director/Board Member	64	01/01/2020